

REMARKS

Claims 1 to 6 as amended are present for purposes of prosecution.

Reconsideration of the rejection of this application is respectfully requested in view of the above amendments and the following remarks.

Claims 1 to 6 are rejected.

Amendments to Claims

Claims 1 and 3, the only independent claims present have been amended to delete “diabetes”, “psoriasis”, “atherosclerosis” and “rheumatoid arthritis” from the conditions treated in accordance with the present invention.

Claims 1 to 6 are rejected under 35 U.S.C. §103(a) as being unpatentable over Hunt et al. The Examiner maintains that Hunt teaches that pyrrolotriazine compounds “can be used in methods of treating cancer, psoriasis, arthritis, inflammation, autoimmune disease, and diabetic retinopathy.” The only “arthritis” condition disclosed by Hunt et al. is rheumatoid arthritis. Hunt et al. makes no indication as to what conditions are covered by inflammation and autoimmune disease.

Independent Claims 1 to 3 have been amended to delete diabetes, psoriasis, atherosclerosis and rheumatoid arthritis.

There is no disclosure or suggestion in Hunt et al. of a method for treating any of “asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammation disease, inflammatory bowel disease, osteoporosis, graft vs. host rejection, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis” as claimed in Applicants’ method of treatment as defined in Claims 1 to 6.

In view of the foregoing, it is submitted that Claims 1 to 6 overcome all formal objections and are patentable over Hunt et al. Accordingly, it is believed that Claims 1 to 6 are in condition for allowance.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department

/Burton Rodney, Reg. No. 22,076/  
Burton Rodney

P.O. Box 4000  
Princeton, NJ 08543-4000  
Phone: 609-252-4336  
Date:

Attorney for Applicants